Literature DB >> 31923766

Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo.

Veronica Bisagno1, Maria Alejandra Bernardi2, Sara Sanz Blasco3, Francisco J Urbano4, Edgar Garcia-Rill5.   

Abstract

The pedunculopontine nucleus (PPN) has long been known to be part of the reticular activating system (RAS) in charge of arousal and REM sleep. We previously showed that in vitro exposure to a HDAC Class I and II mixed inhibitor (TSA), or a specific HDAC class IIa inhibitor (MC 1568), decreased PPN gamma oscillations. Given the lack of information on systemic in vivo treatments on neuronal synaptic properties, the present study was designed to investigate the systemic effect of HDAC inhibitors (HDACi) on PPN rhythmicity. Rat pups were injected (acute, single dose) with TSA (4 or 20 mg/kg), MC1568 (4 or 20 mg/kg), or MS275 (20 or 100 mg/kg). Our results show that MC1568 (20 mg/kg) reduced mean frequency of PPN oscillations at gamma band, while increasing mean input resistance (Rm) of PPN neurons. For TSA (4 and 20 mg/kg), we observed reduced mean frequency of oscillations at gamma band and increased mean Rm of PPN neurons. Systemic administration of 20 mg/kg MC1568 and TSA effects on Rm were washed out after 60 min of in vitro incubation of PPN slices, suggesting an underlying functional recovery of PPN calcium-mediated gamma band oscillations over time. In addition, at a lower dose, 4 mg/kg, MC1568 and TSA induced higher mean amplitude gamma oscillations. Blocking HDAC class I might not have deleterious effects on gamma activity, but, more importantly, the inhibition of HDAC class I (at 100 mg/kg) increased gamma band oscillations. In conclusion, the present results in vivo validate our previous findings in vitro and further expand information on the effects of HDAC inhibition on PPN rhythmicity. PPN neurons require normal activity of HDAC class IIa in order to oscillate at gamma band.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arousal; Calcium channels. Calcium currents; Gamma oscillations; MC1568; MS275; Neuroepigenetics; Trichostatin A

Year:  2019        PMID: 31923766      PMCID: PMC7029427          DOI: 10.1016/j.neuropharm.2019.107922

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  36 in total

1.  Gamma band activity in the developing parafascicular nucleus.

Authors:  Nebojsa Kezunovic; James Hyde; Christen Simon; Francisco J Urbano; D Keith Williams; Edgar Garcia-Rill
Journal:  J Neurophysiol       Date:  2011-11-16       Impact factor: 2.714

Review 2.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

3.  Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism.

Authors:  Luigi Formisano; Natascia Guida; Valeria Valsecchi; Maria Cantile; Ornella Cuomo; Antonio Vinciguerra; Giusy Laudati; Giuseppe Pignataro; Rossana Sirabella; Gianfranco Di Renzo; Lucio Annunziato
Journal:  J Neurosci       Date:  2015-05-13       Impact factor: 6.167

4.  Cholinergic modulation of fast inhibitory and excitatory transmission to pedunculopontine thalamic projecting neurons.

Authors:  Meijun Ye; Abdallah Hayar; Beau Strotman; Edgar Garcia-Rill
Journal:  J Neurophysiol       Date:  2010-02-24       Impact factor: 2.714

5.  Modulation of gamma oscillations in the pedunculopontine nucleus by neuronal calcium sensor protein-1: relevance to schizophrenia and bipolar disorder.

Authors:  Stasia D'Onofrio; Nebojsa Kezunovic; James R Hyde; Brennon Luster; Erick Messias; Francisco J Urbano; Edgar Garcia-Rill
Journal:  J Neurophysiol       Date:  2014-11-05       Impact factor: 2.714

6.  Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.

Authors:  Clifton Lee Dalgard; Kurtis R Van Quill; Joan M O'Brien
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Nicotinamide pharmacokinetics in patients.

Authors:  J Dragovic; S H Kim; S L Brown; J H Kim
Journal:  Radiother Oncol       Date:  1995-09       Impact factor: 6.280

Review 8.  ALS and FTD: an epigenetic perspective.

Authors:  Veronique V Belzil; Rebecca B Katzman; Leonard Petrucelli
Journal:  Acta Neuropathol       Date:  2016-06-09       Impact factor: 17.088

9.  Class II histone deacetylases require P/Q-type Ca2+ channels and CaMKII to maintain gamma oscillations in the pedunculopontine nucleus.

Authors:  Francisco J Urbano; Verónica Bisagno; Susan Mahaffey; Sang-Hun Lee; Edgar Garcia-Rill
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

10.  Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.

Authors:  L Sanderson; G W Taylor; E O Aboagye; J P Alao; J R Latigo; R C Coombes; D M Vigushin
Journal:  Drug Metab Dispos       Date:  2004-07-21       Impact factor: 3.922

View more
  1 in total

1.  Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson's disease.

Authors:  Maxime Fougère; Cornelis Immanuel van der Zouwen; Joël Boutin; Kloé Neszvecsko; Philippe Sarret; Dimitri Ryczko
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-26       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.